Table 6.
Annual cost reductions in hypothetical scenarios 1 and 2 between 2020 and 2060
| Scenario 1: reduction in projected OAO-prevalence by 5% | Scenario 2: keeping OAO-prevalence among men, women, boys and girls at 2019 levels through 2060 | |||
| Average annual cost reduction (billions of 2019 US$) | Percentage cost reduction (%) | Average annual cost reduction (billions of 2019 US$) | Percentage cost reduction (%) | |
| Income group | ||||
| Low | 1.4 | 11.1 | 6.9 | 34.1 |
| Lower middle | 41.2 | 9.3 | 231.2 | 31.6 |
| Upper middle | 219.7 | 6.6 | 1491.1 | 27.4 |
| High | 167.9 | 5.9 | 476.0 | 13.4 |
| WHO region | ||||
| AFR | 5.7 | 7.8 | 29.0 | 27.6 |
| EMR | 12.2 | 4.8 | 44.2 | 12.6 |
| EUR | 60.3 | 6.1 | 151.2 | 12.7 |
| AMR | 93.9 | 5.1 | 285.7 | 12.7 |
| SEA | 38.0 | 9.3 | 249.2 | 34.8 |
| WPR | 220.2 | 7.4 | 1445.8 | 28.7 |
AFR, Africa; AMR, the Americas; EMR, Eastern Mediterranean; EUR, Europe; OAO, overweight and obesity; SEA, South-East Asian; WPR, Western Pacific.